Baraliakos X, et al. Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial. ACR 2018, abstract L13.
Anti-C5a-antilichaam vilobelimab veilig bij ernstige COVID-19
feb 2021 | Pneumonie, Virale infecties